본문바로가기


Drug Discovery





페이지 위치

Platform

> Drug Discovery > Platform


Platform

The core competitiveness of Future Medicine is that it has its own Nuleoside Library platform.

In other words, we derive the drugs required by the market from the company's library and find new drug candidates for each indication. Current drug candidates are stored in this library. This library is the knowledge and experience of CTOs and researchers who have focused on the Nuleoside field for decades.

In this library, in-vivo, in-vitro, animal experiments and toxicity tests are being conducted by finding candidate substances that are currently suitable for the development of therapeutic drugs or developing rare or incurable diseases

During the various experiments, we will proceed to Phase 1 and Phase 2 of the treasure bill, which has a much higher success rate as a new drug. We will deliver the technology to leading pharmaceutical companies in Korea and abroad with excellent results.

Why nucleoside

By adopting strategies utilizing pathways and identifying new ways of improving success and delivery time, Future Medicine focuses on preclinical and clinical stages after identifying lead candidates which are generated from external biotech, universities or research institutes where target identification and proof of concept studies are completed.

Tumor
AML Prostate tumor Lung cancer
Inflammation
Asthma Atopic dermatitis RA
Ophthalmology
Glaucoma Dry Eye
Fibrosis
Chronic kidney disease NASH
Virus
MERS Zika Chikungunya

Adenosine receptor subtypes, mechanisms of action, and clinical effects

There are many drugs in this category. For examples, Gemcitabine for pancreatic cancer, Acyclovir for herpes simplex virus infection, Sofosbuvir for type C liver cancer, etc. Among these, Sofosbuvir is the blockbuster and sold around 10 billion in US Dollar last year(2015) within the US market

E. De Clercq, J. Clin. Virol., 2004, 30, 115-133.

In this category, there are carbo-cyclic nucleoside, acyclic nucleos(t)ide, L-nucleoside and antisense oligonucleotide.
Especially, the Entecarvir for the hepatitis B is ranked as the blockbuster in that it was sold 169 million in US Dollar for Korea market during the year 2015.

E. De Clercq, J. Clin. Virol., 2004, 30, 115-133.

There are many Nucleoside derivatives currently used in anti-cancer clinical trials in worldwide.As Azacytidine is a DNA methyltranferase inhibitor, it is widely used on an epigenetic study as well.

  • Platform
  • Why Nucleoside


페이지 맨 위로 이동